Ovid Therapeutics (OVID) Current Assets (2016 - 2026)

Ovid Therapeutics has reported Current Assets for 11 years, with the latest figure at $160.1 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 248.74% year-over-year to $160.1 million; the trailing twelve-month figure through Mar 2026 stood at $160.1 million (up 248.74% YoY), and the FY2025 full-year result was $74.4 million, up 32.94% from the prior year.
• Current Assets for Q1 2026 stood at $160.1 million, up from $74.4 million in the prior quarter.
• The five-year high for Current Assets was $170.1 million in Q1 2022, with the low at $28.8 million in Q3 2025.
• Historically, Current Assets has averaged $98.1 million across 5 years, with a median of $93.2 million in 2024.
• Annual changes were most pronounced in 2025 — Current Assets plunged 56.21% — and 2026, when it jumped 248.74%.
• Ovid Therapeutics' Current Assets stood at $131.4 million in 2022, then retreated by 16.58% to $109.6 million in 2023, then sank by 48.96% to $55.9 million in 2024, then soared by 32.94% to $74.4 million in 2025, then surged by 115.34% to $160.1 million in 2026.
• The last three Current Assets figures came in at $160.1 million (Q1 2026), $74.4 million (Q4 2025), and $28.8 million (Q3 2025), per Business Quant data.